30 mg Retatrutide Vials: What the Phase 2 Trial Actually Tested
The Phase 2 trial studied weekly doses from 1 to 12 mg. It did not test a 30 mg vial or report BAC-water reconstitution volumes.
FormBlends Editorial Research · Updated 2026-09-27
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Direct answer: The 2023 Phase 2 obesity trial did not study a 30 mg vial or publish a BAC-water reconstitution volume. It studied assigned weekly retatrutide doses from 1 mg to 12 mg. A vial label amount and a trial dose describe different quantities.
What the Phase 2 trial assigned
The randomized trial enrolled 338 adults with obesity or overweight plus a weight-related condition. The seven groups below show the assigned target dose and, where applicable, the trial initial dose. Participants received the study intervention once weekly for 48 weeks.
| Assigned group | Initial dose | What the paper reports |
|---|---|---|
| 1 mg | 1 mg | Weekly target dose |
| 4 mg, lower start | 2 mg | Weekly target dose, with gradual escalation |
| 4 mg, higher start | 4 mg | Weekly target dose, with gradual escalation |
| 8 mg, lower start | 2 mg | Weekly target dose, with gradual escalation |
| 8 mg, higher start | 4 mg | Weekly target dose, with gradual escalation |
| 12 mg | 2 mg | Weekly target dose, with gradual escalation |
| Placebo | Not applicable | Comparator group |
For target doses of 4 mg or more, the protocol escalated every four weeks for up to 12 weeks. This table reports research assignments, not vial contents or preparation instructions.
Why a vial amount does not give a water volume
Milligrams describe mass. Milliliters describe volume. The trial publication and NCT04881760 registry report the assigned doses and study schedule, but they do not specify a 30 mg vial or a BAC-water volume for one. The 30 mg figure therefore cannot be matched to a study-validated reconstitution amount.
Concentration is calculated from the mass and final solution volume, but that equation alone does not establish which volume was used or studied. Search-result answers that present one volume as if the Phase 2 trial supplied it confuse a vial label with the trial protocol.
What this page can establish
The primary trial provides a precise comparison of target doses, starting doses, escalation intervals and follow-up. It does not answer how a separate 30 mg vial was made. Keeping those questions separate makes the evidence easier to check and prevents a research schedule from being misread as a vial specification.